ARIMIDEXÂ® (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor.
ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
The effectiveness of ARIMIDEX in early breast cancer is based on an analysis of recurrence-free survival in patients treated for a median of 31 months (see CLINICAL PHARMACOLOGY
-- Clinical Studies subsection). Further follow-up of study patients will be required to determine long-term outcomes.
ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.
Media Articles Related to Arimidex (Anastrozole)
Less Treatment for More Benefit in Breast Cancer?
Source: Medscape General Surgery Headlines [2016.08.26]
An expert panel at ASCO weighed in on whether current genomic tools can be relied on for a yay or nay regarding specific uses of chemotherapy, radiation, and surgery in breast cancer.
MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo
Source: Medscape Hematology-Oncology Headlines [2016.08.26]
The large European MINDACT study shows that the 70-gene signature test MammaPrint, used in conjunction with clinical risk, could prevent chemo use in 46% of patients.
Medscape Medical News
Risk for Breast Cancer With HRT Higher Than Thought?
Source: Medscape Diabetes & Endocrinology Headlines [2016.08.24]
Hormone replacement therapy with a combination of estrogen and progestogen triples the risk for breast cancer, a new study concludes.
Medscape Medical News
Inflammatory Breast Cancer
Source: MedicineNet Breast Lumps In Women Specialty [2016.08.24]
Title: Inflammatory Breast Cancer
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 8/24/2016 12:00:00 AM
Expecting the worst increases side-effects in breast cancer patients receiving adjuvant hormone therapy
Source: Breast Cancer News From Medical News Today [2016.08.23]
A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer has found that the number and seriousness of side-effects they experienced were...
Published Studies Related to Arimidex (Anastrozole)
Lipid profiles within the SABRE trial of anastrozole with and without
Lipid profiles in women with early breast cancer receiving anastrozole with or
without risedronate were examined within an international Phase III/IV study to
assess for possible treatment related changes. Postmenopausal women with hormone
receptor-positive breast cancer were assigned to 1 of 3 strata by risk of
Weight change associated with anastrozole and tamoxifen treatment in
postmenopausal women with or at high risk of developing breast cancer. 
Weight gain is commonly reported by breast cancer patients on tamoxifen or
aromatase inhibitors. Since weight gain may impact on outcome and compliance we
have prospectively assessed the effects of these agents on weight change in three
randomised trials for the treatment or prevention of breast cancer...
Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy
Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence,
crossover study. 
formulations in healthy male adult volunteers... CONCLUSION: The test and reference formulations had similar PK parameters and
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. 
goserelin for early breast cancer in the neoadjuvant setting... INTERPRETATION: Given its favourable risk-benefit profile, the combination of
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Clinical Trials Related to Arimidex (Anastrozole)
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer [Active, not recruiting]
Over the last 3 decades, a steady shift has occurred in the management of breast cancer.
Because it was traditionally viewed as a local disease, many advocated the use of radical
surgery to achieve maximum survival benefit. This view has been slowly replaced by a broader
biologic view that recognizes the often systemic nature of breast cancer, even when it
appears to be localized to the breast. Results from randomized clinical trials have
demonstrated that less extensive surgery, or lumpectomy plus radiation therapy, are optimal
for local management of early breast cancer. In addition to the less radical approach to
surgical treatment of breast cancer, other randomized clinical trials have established the
value of postoperative systemic therapy in improving overall survival by eradicating
micrometastatic disease, the major cause of mortality from breast cancer. Despite the
well-documented benefits of adjuvant systemic therapy, it is not effective in preventing
death from breast cancer in all patients who are candidates for such treatment. The worth of
such therapy can only be judged in retrospect upon disease relapse, a time when breast
cancer is nearly always incurable. Currently, there are few reliable methods to predict the
success or failure of a particular postoperative treatment modality, and better ways to
predict and optimize outcome are needed.
Combination endocrine therapy: Using endocrine agents with different mechanisms of action
together has the potential advantage of more effectively blocking ER signaling, thus
improving the efficacy of such agents against breast cancer. In the past, attempts to
combine endocrine agents for ER-positive breast cancer have had mixed results, depending on
the setting and the patient population studied.
Endocrine agents without any agonist effect could potentially be used in combination with
aromatase inhibitors, under the rationale that the combination would maximally blockade
estrogen receptor signaling, thus potentially improving the antitumor effect. Fulvestrant
(FASLODEX) is a pure estrogen antagonist with no known agonist effect; thus, it has the
potential to provide additional benefit when combined with an aromatase inhibitor. This
concept provides the rationale for using the combination of anastrazole and fulvestrant in
Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects [Completed]
This study is to investigate whether anastrozole ODF is bioequivalent with Arimidex tablet
after a single oral administration of each anastrozole formulation.
Liver Safety Under Upfront Arimidex vs Tamoxifen [Completed]
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20
mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
The second objectives are to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen
20 mg once daily as adjuvant treatment in terms of: incidences of abnormal liver function
test, and time to treatment failure.
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. [Active, not recruiting]
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or
Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or
metastatic breast cancer who have not had prior hormonal treatment.
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid [Active, not recruiting]
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second,
the comparison of zoledronate added to standard adjuvant therapy with controls according to
disease-free survival (DFS) in premenopausal patients with non-metastatic breast cancer
treated with tamoxifen or anastrozole. To assess whether zoledronate added to standard
adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal
blockade combined with an antiestrogen or aromatase inhibitor.
Reports of Suspected Arimidex (Anastrozole) Side Effects
Neoplasm Malignant (113),
Hot Flush (79),
Breast Cancer (78),
Pain in Extremity (67),
Drug Dose Omission (63),
Alopecia (56), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Arimidex has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Arimidex review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || post breast cancer|
|Dosage & duration:|| || 1mg taken once a day for the period of 5 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Considered beneficial for post menapausal women to prevent the recurrance of breast cancer. It is a hormone blocker that stops the production of estrogen. Many breast cancer tumors are estrogen positive and thrive in the presence of estrogen.|
|Side effects:|| || I had no side effects but possible side effects are, constipation, headaches, nausea, diahrea, weight gain.|
|Comments:|| || One 1mg pill once a day for five years following treatment of breast cancer in post menapausal women.|
Page last updated: 2016-08-26